OncoSec Medical Inc ONCS Stock Quotes and Insider News

Insider Chart Past 6 Months

Technical Chart

Filings by transaction date

May 03, 2021 (filed on May 04, 2021)

Insider Name:

DelAversano Robert J

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-453

Price:

$4.86
Apr 30, 2021 (filed on May 04, 2021)

Insider Name:

O'Connor Daniel J.

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-3,172

Price:

$4.86
Apr 16, 2021 (filed on Apr 26, 2021)

Insider Name:

China Grand Pharmaceutical & Healthcare Holdings Ltd

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

281,968

Price:

$3.45
Apr 16, 2021 (filed on Apr 26, 2021)

Insider Name:

China Grand Pharmaceutical & Healthcare Holdings Ltd

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

1,409,838

Price:

$3.45
Feb 18, 2021 (filed on Feb 23, 2021)

Insider Name:

Alpha Holdings, Inc.

Ownership Type:

Direct Ownership

Securities:

Warrants to Purchase Common Stock

Nature of Transaction:

X - in- or at-the-money exercise

# or value acquired/disposed of:

368,250

Price:

$0.01
Feb 18, 2021 (filed on Feb 23, 2021)

Insider Name:

Alpha Holdings, Inc.

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

X - in- or at-the-money exercise

# or value acquired/disposed of:

368,250

Price:

$3.45
Feb 02, 2021 (filed on Feb 17, 2021)

Insider Name:

Leuthner Brian A

Ownership Type:

Direct Ownership

Securities:

Stock Option(Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

150,000

Price:

--
Feb 01, 2021 (filed on Feb 03, 2021)

Insider Name:

DelAversano Robert J

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

8,750

Price:

--
Feb 01, 2021 (filed on Feb 02, 2021)

Insider Name:

O'Connor Daniel J.

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-3,413

Price:

$7.71
Jan 25, 2021 (filed on Jan 27, 2021)

Insider Name:

China Grand Pharmaceutical & Healthcare Holdings Ltd

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

677,839

Price:

$5.45

Filings by filing date

Apr 30, 2021 (filed on May 04, 2021)

Insider Name:

O'Connor Daniel J.

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-3,172

Price:

$4.86
May 03, 2021 (filed on May 04, 2021)

Insider Name:

DelAversano Robert J

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-453

Price:

$4.86
Apr 16, 2021 (filed on Apr 26, 2021)

Insider Name:

China Grand Pharmaceutical & Healthcare Holdings Ltd

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

281,968

Price:

$3.45
Apr 16, 2021 (filed on Apr 26, 2021)

Insider Name:

China Grand Pharmaceutical & Healthcare Holdings Ltd

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

1,409,838

Price:

$3.45
Feb 18, 2021 (filed on Feb 23, 2021)

Insider Name:

Alpha Holdings, Inc.

Ownership Type:

Direct Ownership

Securities:

Warrants to Purchase Common Stock

Nature of Transaction:

X - in- or at-the-money exercise

# or value acquired/disposed of:

368,250

Price:

$0.01
Feb 18, 2021 (filed on Feb 23, 2021)

Insider Name:

Alpha Holdings, Inc.

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

X - in- or at-the-money exercise

# or value acquired/disposed of:

368,250

Price:

$3.45
Feb 02, 2021 (filed on Feb 17, 2021)

Insider Name:

Leuthner Brian A

Ownership Type:

Direct Ownership

Securities:

Stock Option(Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

150,000

Price:

--
Feb 01, 2021 (filed on Feb 03, 2021)

Insider Name:

DelAversano Robert J

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

8,750

Price:

--
Feb 01, 2021 (filed on Feb 02, 2021)

Insider Name:

O'Connor Daniel J.

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-3,413

Price:

$7.71
Jan 25, 2021 (filed on Jan 27, 2021)

Insider Name:

China Grand Pharmaceutical & Healthcare Holdings Ltd

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

677,839

Price:

$5.45

News

Biz Brief

Sector: Healthcare	Industry: Biotechnology & Medical Research

See Regulatory Filings on SEC

Company Contact

Address:	24 N Main St PENNINGTON NJ 08534-2218
Tel:	N/A
Website:	oncosec.com
IR:	See website

Key People

Margaret Dalesandro Independent Chairman of the Board	Daniel J. O'Connor President, Chief Executive Officer, Director	Brian A. Leuthner Chief Operating Officer
Robert J. DelAversano Principal Accounting Officer, Controller	Joe Smith Vice President - Business Development

Business Overview

OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company's core platform technology, ImmunoPulse, is a drug-device therapeutic modality comprised of intratumoral electroporation (EP) delivery device. The ImmunoPulse platform is designed to deliver plasmid deoxyribonucleic acid (DNA)-encoded drugs directly into a solid tumor and promote an immunological response against cancer. The ImmunoPulse device can be adapted to treat different tumor types and consists of an electrical pulse generator, a reusable handle and disposable applicators. The Company's lead product candidate is a DNA-encoded interleukin-12 (IL-12) called tavokinogene telseplasmid (TAVO).

Financial Overview

For the nine months ended 30 April 2021, OncoSecMedical Inc revenues was not reported. Net loss decreasedless than 1% to $33.4M. Net income also reflects Generaland administrative - Balancing decrease of 54% to $6.7M(expense), Foreign currency exchange loss, net increasefrom $257K (expense) to $187K (income), offset by Researchand development - Balancing increase of 47% to $24.7M(expense).

Employees:	42 as of Jul 31, 2020

Reporting Currency:	U.S. Dollars
Enterprise value:	$77.27M as of Apr 30, 2021
Annual revenue (TTM):	$0.00M as of Apr 30, 2021
EBITDA (TTM):	-$44.44M as of Apr 30, 2021
Net annual income (TTM):	-$42.34M as of Apr 30, 2021
Free cash flow (TTM):	-$43.25M as of Apr 30, 2021
Net Debt Last Fiscal Year:	N/A
Shares outstanding:	39,185,251 as of Jun 11, 2021
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

INK Ultra Money Free

INK Ultra Money Videos

OncoSec Medical Inc (OQ:ONCS)